While the pandemic reduced patient visits with an impact on some areas including neuroscience at Takeda Pharmaceutical Co. Ltd., this was offset by gains for certain other products and lower travel expenses, meaning the overall net business impact for the Japanese firm last fiscal year was “not material.”
In announcing its results for the 12 months ended 31 March, Japan’s largest pharma company said it had managed to...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
